Arcturus Therapeutics Holdings Inc. current report, 23 September 2026

Full document

Arcturus Therapeutics Holdings Inc. Form 8-K Summary

Business Context and Reporting Period

Arcturus Therapeutics Holdings Inc. filed a Form 8-K dated September 23, 2026, under Item 7.01, Regulation FD Disclosure. The company presented an overview of ARCT-810 Phase 2 clinical data and provided an update on its mRNA delivery platform.

Financial and Operating Metrics

This filing does not provide financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, or other quantitative financial metrics. The filing text does not provide a clear value for any such measures.

Material Changes Versus the Prior Comparable Period

The filing does not present period-over-period financial comparisons. The disclosed developments are an update regarding ARCT-810 Phase 2 clinical data and the company’s mRNA delivery platform.

Guidance, Outlook, Risks, and Unusual Items

  • The filing does not state formal financial guidance or updated corporate outlook.
  • The filing references a presentation and press release furnished as Exhibits 99.1 and 99.2, respectively; their substantive contents are not included in the provided filing text.
  • The Item 7.01 information, presentation, and press release are furnished and are not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
  • The materials are not incorporated by reference into other SEC filings, regardless of general incorporation language.
  • Clinical-development, regulatory, manufacturing, financing, and commercialization risks are not detailed in the provided text.

Important Facts for Investors to Verify

  1. Review Exhibits 99.1 and 99.2 for the detailed ARCT-810 Phase 2 results, statistical information, safety data, and management commentary.
  2. Verify the development stage, next milestones, regulatory plans, and potential timing for ARCT-810.
  3. Review the company’s latest periodic filing for cash, liquidity, operating expenses, debt, cash runway, and financing requirements.
  4. Assess whether the clinical data represent interim or final results and whether they support any planned pivotal study or regulatory submission.